先通医药完成C轮融资,用于放射药项目临床前开发及临床研究

2020-09-08 林怡龄 亿欧

今年7月,先通医药完成了C轮融资,共募集资金2.8亿元。物明投资继天使轮之后继续追加投资,同辐基金、国药资本、国科嘉和及荷塘创投跟投。本次募集资金主要用于放射药项目临床前开发及临床研究,助力推进各个项

今年7月,先通医药完成了C轮融资,共募集资金2.8亿元。物明投资继天使轮之后继续追加投资,同辐基金、国药资本、国科嘉和及荷塘创投跟投。本次募集资金主要用于放射药项目临床前开发及临床研究,助力推进各个项目的研发进度。

先通医药成立于2004年,最初的目标是在中国开发、生产和商业化进口药和仿制药。随后,其将业务不断拓展,成为一家专业从事放射性药物和单克隆抗体药物研发、生产、临床学术推广的创新型医药企业。

根据其核素药物领域的发展现状,先通医药确定了其自主创新的研发产品线,涵盖神经退行性疾病、血管、肿瘤等领域的精准诊断和靶向治疗药物。

而在单克隆抗体药物领域,先通医药则专注于抗体类生物药早期研发,在研产品涉及肿瘤、神经退行性疾病、自身免疫病等多个领域。其中,针对死亡受体5的单抗类生物药CTB006已获得CFDA批准的临床研究批件,目前处于临床I期。

依托在放射性药物和单克隆抗体药物领域的研发资源,先通医药正在研究将抗体药物与放射性核素相结合,开发全球创新性的肿瘤诊断及放射免疫治疗药物。

2018年,先通医药提交了终止股票挂牌的申请,正式从新三板撤下。同一年,其获美国国立卫生研究院(NIH)核素治疗前列腺癌新药全球授权。依照美国相关法律,NIH将其放射性核素治疗转移性去势难治性前列腺癌的发明授予先通医药,独家用于全球的开发与商业化。

2017年,先通医药则与原子高科就共同推动阿尔茨海默症诊断新药Neuraceq在中国上市事宜签署合作框架协议。β-淀粉样蛋白在大脑沉积形成淀粉样斑块是阿尔兹海默症(AD)特征性病理改变,也是AD诊断的“金标准”。

而Neuraceq正是FDA已批准的针对该靶点的诊断新药,能够客观、定量地反映患者脑中淀粉样斑块的聚集水平,为AD的诊断、疾病进展以及药物疗效的评价提供科学依据。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=884868, encodeId=58c188486886, content=阅读谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Sep 13 08:09:43 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410055, encodeId=a54d1410055a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459108, encodeId=42431459108ba, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048150, encodeId=95f8104815094, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 09 02:18:43 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883744, encodeId=9954883e4475, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200923/8af58a8d80fa4d3e83e7cc9686930f6e/4638f64094bd40a4bb51a09cacaee275.jpg, createdBy=33335378595, createdName=ms9000001531324985, createdTime=Tue Sep 08 23:44:41 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883741, encodeId=b5e5883e4143, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cd12498301, createdName=130*****887<手机用户>3391, createdTime=Tue Sep 08 23:37:23 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-13 刘煜

    阅读谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=884868, encodeId=58c188486886, content=阅读谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Sep 13 08:09:43 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410055, encodeId=a54d1410055a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459108, encodeId=42431459108ba, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048150, encodeId=95f8104815094, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 09 02:18:43 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883744, encodeId=9954883e4475, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200923/8af58a8d80fa4d3e83e7cc9686930f6e/4638f64094bd40a4bb51a09cacaee275.jpg, createdBy=33335378595, createdName=ms9000001531324985, createdTime=Tue Sep 08 23:44:41 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883741, encodeId=b5e5883e4143, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cd12498301, createdName=130*****887<手机用户>3391, createdTime=Tue Sep 08 23:37:23 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-10 cathymary
  3. [GetPortalCommentsPageByObjectIdResponse(id=884868, encodeId=58c188486886, content=阅读谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Sep 13 08:09:43 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410055, encodeId=a54d1410055a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459108, encodeId=42431459108ba, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048150, encodeId=95f8104815094, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 09 02:18:43 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883744, encodeId=9954883e4475, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200923/8af58a8d80fa4d3e83e7cc9686930f6e/4638f64094bd40a4bb51a09cacaee275.jpg, createdBy=33335378595, createdName=ms9000001531324985, createdTime=Tue Sep 08 23:44:41 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883741, encodeId=b5e5883e4143, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cd12498301, createdName=130*****887<手机用户>3391, createdTime=Tue Sep 08 23:37:23 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-10 zhao4618
  4. [GetPortalCommentsPageByObjectIdResponse(id=884868, encodeId=58c188486886, content=阅读谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Sep 13 08:09:43 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410055, encodeId=a54d1410055a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459108, encodeId=42431459108ba, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048150, encodeId=95f8104815094, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 09 02:18:43 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883744, encodeId=9954883e4475, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200923/8af58a8d80fa4d3e83e7cc9686930f6e/4638f64094bd40a4bb51a09cacaee275.jpg, createdBy=33335378595, createdName=ms9000001531324985, createdTime=Tue Sep 08 23:44:41 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883741, encodeId=b5e5883e4143, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cd12498301, createdName=130*****887<手机用户>3391, createdTime=Tue Sep 08 23:37:23 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-09 CHANGE

    又是钱!医学需要投资呀,赞!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=884868, encodeId=58c188486886, content=阅读谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Sep 13 08:09:43 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410055, encodeId=a54d1410055a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459108, encodeId=42431459108ba, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048150, encodeId=95f8104815094, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 09 02:18:43 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883744, encodeId=9954883e4475, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200923/8af58a8d80fa4d3e83e7cc9686930f6e/4638f64094bd40a4bb51a09cacaee275.jpg, createdBy=33335378595, createdName=ms9000001531324985, createdTime=Tue Sep 08 23:44:41 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883741, encodeId=b5e5883e4143, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cd12498301, createdName=130*****887<手机用户>3391, createdTime=Tue Sep 08 23:37:23 CST 2020, time=2020-09-08, status=1, ipAttribution=)]
    2020-09-08 ms9000001531324985

    学习了

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=884868, encodeId=58c188486886, content=阅读谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2017/04/21/72142930668371951a41ef4ea4b233e6.jpg, createdBy=dcbc1715228, createdName=刘煜, createdTime=Sun Sep 13 08:09:43 CST 2020, time=2020-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1410055, encodeId=a54d1410055a8, content=<a href='/topic/show?id=2c1c35262a9' target=_blank style='color:#2F92EE;'>#医药#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=35262, encryptionId=2c1c35262a9, topicName=医药)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=36f62754598, createdName=cathymary, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1459108, encodeId=42431459108ba, content=<a href='/topic/show?id=c2258886959' target=_blank style='color:#2F92EE;'>#融资#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=88869, encryptionId=c2258886959, topicName=融资)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=61b96121455, createdName=zhao4618, createdTime=Thu Sep 10 14:18:43 CST 2020, time=2020-09-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1048150, encodeId=95f8104815094, content=又是钱!医学需要投资呀,赞!, beContent=null, objectType=article, channel=null, level=null, likeNumber=52, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=CHANGE, createdTime=Wed Sep 09 02:18:43 CST 2020, time=2020-09-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883744, encodeId=9954883e4475, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200923/8af58a8d80fa4d3e83e7cc9686930f6e/4638f64094bd40a4bb51a09cacaee275.jpg, createdBy=33335378595, createdName=ms9000001531324985, createdTime=Tue Sep 08 23:44:41 CST 2020, time=2020-09-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=883741, encodeId=b5e5883e4143, content=已读, beContent=null, objectType=article, channel=null, level=null, likeNumber=77, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4cd12498301, createdName=130*****887<手机用户>3391, createdTime=Tue Sep 08 23:37:23 CST 2020, time=2020-09-08, status=1, ipAttribution=)]

相关资讯

Nat BME : 简易旋转体用于泌尿系统感染检测

在资源有限的环境中,现代实验室中使用的传统医疗设备面临着诸如电源中断、缺乏熟练专业人员、恶劣环境条件和缺乏快速数据连接等障碍。从而导致复杂的临床并发症但并非所有设备都能用于资源有限的环境,成本。

journal of Neurology, Neurosurgery & Psychiatry:有症状和临床症状出现前遗传性颞颞叶变性的早期症状

额颞叶痴呆(FTD)的临床异质性使用于临床试验的生物标志物的鉴定变得复杂,这些生物标志物在预诊断阶段可能很敏感。目前尚不清楚临床前时期的认知或行为变化是否可预测遗传状态或转换为临床FTD。第一个目标是

再鼎1.9亿美元引进再生元CD20xCD3双抗进展,已获批临床

亿欧大健康9月8日消息,今日CDE官网公示,再鼎医药申报的REGN1979注射液获批5项临床默示许可,适应症为“既往全身治疗后复发或难治的B细胞非霍奇金淋巴瘤(B-NHL)患者&rdquo

!百利药业四特异性抗体获批临床

据CDE官网显示,日前,百利药业GNC-038四特异性抗体注射液的临床试验申请获得NMPA默示许可,用于复发或难治性非霍奇金淋巴瘤(R/R NHL)、复发或难治性急性淋巴细胞白血病(R/R ALL)和

Nat BME:基于Cas13的SARS-CoV-2RNA检测方法的临床验证

由SARS-CoV-2病毒的传播引起的COVID-19大流行需要快速、敏感和廉价的诊断方法来促进疾病的控制。实时定量PCR和逆转录(RT-qPCR)测量病毒RNA的数量,仍然是SARS-CoV-2病毒

Nat BME:一种低功耗的无线脑机接口在猴子和人身上的试用

电生理设备广泛用于基础神经科学研究中,测量一组神经元(使用脑电图和皮质脑电图)或单个神经元(使用皮层内电极)的活动以了解神经系统的功能。 脑机接口提供了大脑与外部设备之间的直接通信路径。